Rxsight Inc (NQ: RXST )

50.78 +0.58 (+1.16%)
Streaming Delayed Price Updated: 11:10 AM EDT, Oct 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rxsight Inc

< Previous 1 2 3 4 Next >
Chart Of The Day: RxSight - Cashing In On Cataracts
Earnings are estimated to increase 33.30% this year, increase an additional 26.60% next year and continue to compound at an annual rate of 19.00% for the next 5 years 
Via Talk Markets
RxSight, Inc. to Participate in the 34th Annual Oppenheimer Healthcare Conference
From RxSight, Inc.
Via GlobeNewswire
Forecasting The Future: 9 Analyst Projections For RxSight
Via Benzinga
Recap: RxSight Q4 Earnings
Via Benzinga
RxSight, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
From RxSight, Inc.
Via GlobeNewswire
RxSight's Earnings Outlook
Via Benzinga
Stifel Maintains Buy Rating for RxSight: Here's What You Need To Know
Via Benzinga
The Analyst Landscape: 8 Takes On RxSight
Via Benzinga
Breaking Down RxSight: 5 Analysts Share Their Views
Via Benzinga
Earnings Scheduled For February 28, 2024
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. 
Via Benzinga
Analyst Expectations for RxSight's Future
Via Benzinga
RxSight: Q3 Earnings Insights
Via Benzinga
Where RxSight Stands With Analysts
Via Benzinga
RxSight's Earnings: A Preview
Via Benzinga
RxSight, Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
From RxSight, Inc.
Via GlobeNewswire
Insiders are selling these hot stocks on track for higher prices
Insiders are selling these hot stocks and may cap gains in the near term, but long-term gains are in the outlook. Analysts support them and raise their targets. 
Via MarketBeat
Jim Cramer: This Healthcare Stock Is 'Too Risky,' But Shares Jumped 64% Over Past Month
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is "too risky." 
Via Benzinga
3 Stocks to Buy BEFORE They Become Household Names
The best way to find 100 baggers is to invest in undiscovered stock gems that have yet to become household names. 
Via InvestorPlace
The Latest Analyst Ratings for RxSight
Via Benzinga
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on... 
Via Benzinga
RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Financial and Operational Results and 2024 Guidance
From RxSight, Inc.
Via GlobeNewswire
RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference
From RxSight, Inc.
Via GlobeNewswire
RxSight, Inc. Reports Third Quarter 2023 Financial Results
From RxSight, Inc.
Via GlobeNewswire
RxSight, Inc. Educational and Product Announcements for AAO 2023
From RxSight, Inc.
Via GlobeNewswire
RxSight, Inc. to Report Third Quarter Financial Results on November 9, 2023
From RxSight, Inc.
Via GlobeNewswire
RxSight, Inc. to Present at the Wells Fargo Healthcare Conference
From RxSight, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
RxSight, Inc. Reports Second Quarter 2023 Financial Results
From RxSight, Inc.
Via GlobeNewswire
RxSight, Inc. to Report Second Quarter Financial Results on August 7, 2023
From RxSight, Inc.
Via GlobeNewswire
RxSight Is A Potential Acquisition Target: Analyst Highlights How LAL Revenue Mix Could Drive Share Price To $45+
Needham analyst David Saxon reiterated a Buy rating on RxSight, Inc. (NASDAQ: RXST),  
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.